443.33MMarket Cap-3.36P/E (TTM)
2.270High1.840Low33.91MVolume2.180Open2.550Pre Close71.74MTurnover17.33%Turnover RatioLossP/E (Static)197.04MShares3.94052wk High-1.20P/B440.17MFloat Cap1.58052wk Low--Dividend TTM195.63MShs Float120.960Historical High--Div YieldTTM16.86%Amplitude0.700Historical Low2.115Avg Price1Lot Size
Esperion Therapeutics Stock Forum
gone for good ? 😢
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
Esperion Therapeutics (NASDAQ: ESPR) has entered into a licensing agreement with Neopharm Israel for exclusive commercialization rights of NEXLETOL® and NEXLIZET® in Israel. The agreement includes an upfront payment, near-term milestone payments, and tiered royalties on product sales.
Under the agreement terms, Neopharm will rece...
1 min ago
Esperion Partners With Neopharm to Commercialize Nexletol® (Bempedoic Acid) and Nexlizet® (Bempedoic Acid and Ezetimibe) in Israel! Esperion Therapeutics Inc: Under Terms of Agreement, Esperion Will Receive an Upfront and Near-Term Milestone Payments
No comment yet